Friday, September 27, 2013 9:39:32 PM
private transactions exempt from registration, for consideration consisting of
cash paid to the Company and cancellation of debt owed by the Company, all
listed as follows:
DATE
SHARES
ISSUED
NAME OF
PERSON OR
ENTITY
RECEIVING
SHARES
NUMBER OF
SHARES
RESTRICTED
OR FREE
TRADING?
EXEMPTION
ALLOWING
SHARES TO
BE ISSUED
CONSIDERATION
PAID FOR
SHARES
7-21-09 K&L
International
Enterprises,
Inc.
300,000,000 FreeTrading
3(a)(9) $15,000.00
8-21-09 K&L
International
Enterprises,
Inc.
300,000,000 FreeTrading
3(a)(9) $15,000.00
9-23-09 E-Lionhart
Associates,
LLC
350,000,000 FreeTrading
Reg D Rule
504
$50,000.00
10-31-09 E-Lionhart
Associates,
LLC
450,000,000 FreeTrading
Reg D Rule
504
$78,750.00
3-11-10 John S.
Zankowski
Kevin M.
Zankowski
Eric Wolf
David
Weaver
800,000,000
500,000,000
75,000,000
25,000,000
Restricted
Restricted
Restricted
Restricted
Section 4(2)
Section 4(2)
Section 4(2)
Section 4(2)
$80,000.00
$50,000.00
$7500.00
$2500.00
3-15-10 Epic
Worldwide,
4-28-10 Epic
Worldwide,
Inc.
200,000,000 FreeTrading
Reg D Rule
504
$10,000.00
5-03-10 E-Lionhart
Assosciates,
LLC
200,000,000 FreeTrading
Reg D Rule
504
$25,000
5-06-10 E-Lionhart
Associates,
LLC
200,000,000 FreeTrading
Reg D Rule
504
$25,000
5-11-10 E-Lionhart
Associates,
LLC
250,000,000 FreeTrading
Reg D Rule
504
$50,000
5-12-10 Mazuma
Corp.
50,000,000 FreeTrading
3(a)9 $10,000
5-18-10 E-Lionhart
Associates,
LLC
250,000,000 FreeTrading
Reg D Rule
504
$50,000
5-26-10 E-Lionhart
Associates,
LLC
250,000,000 FreeTrading
Reg D Rule
504
$50,000
6-15-10 W.Popham 50,000,000 Restricted $2,500
11-26-10 W.Popham 300,000,000 FreeTrading
3(a)9 $15,000
12-03-10 WB Hunt
Consulting,
Inc.
366,500,000 FreeTrading
3(a)9 $19,974
Part F Exhibits
The following exhibits must be either described in or attached to the disclosure statement:
Item XVIII – Material Contracts
The Issuer has no material contracts that will be required of or performed by t
200,000,000 FreeTrading
3(a)(9) $10,000.00
According to Pink Sheet Guidelines: Version 9.7 Updated on 7/22/2009 21
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM